Analysts name 2 fantastic ASX 200 shares to buy

Here are two ASX 200 shares analysts rate highly…

| More on:
Two male ASX 200 analysts stand in an office looking at various computer screens showing share prices

Image source: Getty Images

The S&P/ASX 200 Index (ASX: XJO) is home to a large number of quality companies with the potential to generate strong returns for investors in the future.

Two that analysts are particularly positive on are listed below. Here’s why they are tipping them as buys right now:

Breville Group Ltd (ASX: BRG)

The first ASX 200 share to look at is Breville. is one of the world’s leading appliance manufacturers. As well as the eponymous Breville brand, it also has the Sage, Kambrook, and Baratza brands.

Breville has been growing at a consistently solid rate for the last decade and looks well-placed to continue this trend over the next decade. This is thanks to the popularity of its brands, its international expansion, acquisitions, favourable consumer trends, and its continued investment in R&D.

Macquarie is very positive on the company’s future and expects further strong growth in the coming years. Last week its analysts retained their outperform rating and $34.37 price target on the company’s shares. The broker notes that rival DeLonghi and one of Breville’s distributors in the US recently reported strong results. It feels this bodes well for Breville’s performance.

ResMed Inc. (ASX: RMD)

Another ASX 200 share that could be a top option is ResMed. It is a medical device company with a focus on the sleep treatment market.

Thanks to its industry-leading products, wide distribution network, and successful acquisitions, ResMed has been growing at a very strong rate over the last few years.

The good news is that thanks to its significant market opportunity, the growing prevalence of sleep disorders, and new product launches, it has been tipped to continue doing so for the foreseeable future. In addition, ResMed’s near term performance is being boosted by a major product recall from rival Philips.

Morgans is a fan of ResMed. Its analysts currently have an add rating and $40.80 price target on its shares. The broker believes ResMed is well-placed as it builds a unique, patient-centric, connected-care digital platform that addresses the main pinch points across the healthcare value chain.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.

*Returns as of January 12th 2022

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Growth Shares